![These highlights do not include all the information needed to use OTEZLA safely and effectively. See full prescribing information for OTEZLA. OTEZLA® (apremilast) tablets, for oral use Initial U.S. approval: 2014 These highlights do not include all the information needed to use OTEZLA safely and effectively. See full prescribing information for OTEZLA. OTEZLA® (apremilast) tablets, for oral use Initial U.S. approval: 2014](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=otezla-06.jpg&id=544787)
These highlights do not include all the information needed to use OTEZLA safely and effectively. See full prescribing information for OTEZLA. OTEZLA® (apremilast) tablets, for oral use Initial U.S. approval: 2014
![The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE) - Reich - 2017 - Journal of The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE) - Reich - 2017 - Journal of](https://onlinelibrary.wiley.com/cms/asset/ebef11de-3d5f-42ee-81ae-7885ec6860a9/jdv14015-fig-0001-m.jpg)
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE) - Reich - 2017 - Journal of
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OTEZLA safely and effec
![Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study - Van Voorhees - 2021 - British Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study - Van Voorhees - 2021 - British](https://onlinelibrary.wiley.com/cms/asset/c4475fc4-a155-4c78-99f0-709cdf681c32/bjd20083-fig-0001-m.jpg)
Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study - Van Voorhees - 2021 - British
![The FDA-approved drug apremilast suppresses alcohol intake: clinical and pre-clinical validation | bioRxiv The FDA-approved drug apremilast suppresses alcohol intake: clinical and pre-clinical validation | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2021/05/15/2021.05.13.444033/F2.large.jpg)